Milestone 9.H
Launch research programs to develop and validate sensitive neuropsychological and behavioral assessment measures to detect and track the earliest clinical manifestations of AD and AD-related dementias.
Success Criteria
-
Development of at least one sensitive neuropsychological assessment measure that has been validated for the detection or tracking of the earliest clinical manifestations of AD and AD-related dementias.
-
Extend ongoing research on social and emotional functioning and decision-making in MCI/AD to identify early behavioral markers of disease.
-
Support research to develop clinical tools for assessment of early deficits in decision-making, motivation and social and emotional functioning in AD.
- Research Implementation Area
- Biomarkers
- Timeline
- 2014–2022
- Status
- Complete
Implementation Activities
Funding Initiatives
- RFA-AG-13-015: Alzheimer's Disease Prevention Trials (R01)
- PAR-14-089: Early Stage Clinical Trials for the Spectrum of Alzheimer's Disease and Age-related Cognitive Decline (R01)
- PAR-16-365: Early Stage Clinical Trials for the Spectrum of Alzheimer's Disease and Age-related Cognitive Decline (R01)
- PAR-18-175: Early Stage Clinical Trials for the Spectrum of Alzheimer's Disease and Age-related Cognitive Decline (R01)
- PAR-18-877: Early Stage Clinical Trials for the Spectrum of Alzheimer's Disease and Age-related Cognitive Decline (R01)
- RFA-AG-15-011: Biomarkers of Alzheimer’s Disease in Down Syndrome (R01)
- PAR-16-448: Basic and Translational Research on Decision Making in Aging and Alzheimer's Disease (R01)
- PAR-16-449: Basic and Translational Research on Decision Making in Aging and Alzheimer's Disease (R21)
- PAR-16-364: Phase III Clinical Trials for the Spectrum of Alzheimer's Disease and Age-related Cognitive Decline (R01)
- RFA-AG-17-052: Alzheimer's Disease Outcomes Research Resource (U2C)
- PAR-18-544: Basic and Translational Research on Decision Making in Aging and Alzheimer's Disease (R01/R21)
- PAR-18-538: Basic and Translational Research on Decision Making in Aging and Alzheimer's Disease (R21)
- PAR-18-581: Emotional Function in Normal Aging and/or MCI and AD/ADRD (R01)
- PAR-18-582: Emotional Function in Normal Aging and/or MCI and AD/ADRD (R21)
- RFA-AG-18-012: Mobile Monitoring of Cognitive Change (U2C)
- RFA-AG-20-050: Low Cost Detection of Cognitive Decline in Clinical Settings (R61/R33)
- RFA-AG-20-051: Low Cost Detection of Cognitive Decline in Clinical (R01)
Research Programs and Resources
- Alzheimer’s Biomarkers Consortium – Down Syndrome (ABC-DS)
- NIA Ongoing Alzheimer’s and Related Clinical Trials and Studies
- Alzheimer’s Prevention Initiative (API)
- Anti-Amyloid Treatment In Asymptomatic Alzheimer’s Disease Study (A4 study)
- Dominantly Inherited Alzheimer's Network Trials Unit - Adaptive Prevention Trial (DIAN-TU)
- The Mobile Toolbox for Monitoring Cognitive Function
- ADNI Psychometrics
- Predictors of Severity in Alzheimer’s Disease
- Optimizing Cognitive Assessment in DIAN with Smartphone-based Burst Testing
- Novel Automated Performance-based ADL Outcomes For Early AD Clinical Trials
- Neurodegeneration In Aging Down Syndrome (NiAD): A Longitudinal Study Of Cognition And Biomarkers of Alzheimer's Disease
- Biomarkers of Alzheimer's Disease In Adults With Down Syndrome
- Clinical Trials to Prevent Alzheimer’s Disease in Down Syndrome
- Emotional Function in Normal Aging and/or MCI and AD/ADRD
- Mobile Toolbox Website